Ironwood Pharmaceuticals ...
3.65
-0.12 (-3.18%)
At close: Jan 14, 2025, 3:59 PM
undefined%
Bid 3.65
Market Cap 584.90M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.01
PE Ratio (ttm) -365.5
Forward PE n/a
Analyst Buy
Ask 4.19
Volume 758,692
Avg. Volume (20D) 1,898,904
Open 3.77
Previous Close 3.77
Day's Range 3.65 - 3.83
52-Week Range 3.06 - 15.70
Beta undefined

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...

Sector Healthcare
IPO Date Feb 3, 2010
Employees 267
Stock Exchange NASDAQ
Ticker Symbol IRWD

Analyst Forecast

According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 200.96% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $92.50M, reflecting a -21.31% YoY shrinking and earnings per share of 0.12.
2 months ago · Source
+4.8%
Ironwood Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
5 months ago · Source
-32.61%
Ironwood Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results and revised its FY24 guidance.